Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO1998023290 A1
Publication typeApplication
Application numberPCT/JP1997/004267
Publication date4 Jun 1998
Filing date21 Nov 1997
Priority date25 Nov 1996
Also published asCA2244256A1, CA2244256C, CN1180844C, CN1214634A, CN1291717C, CN1530111A, CN1535687A, DE69728585D1, DE69728585T2, DE69732868D1, DE69732868T2, DE69737592D1, DE69737592T2, EP0897726A1, EP0897726A4, EP0897726B1, EP1310251A1, EP1310255A1, EP1310255B1, EP1312361A1, EP1327444A1, EP1327444B1, US6174891, US6316461
Publication numberPCT/1997/4267, PCT/JP/1997/004267, PCT/JP/1997/04267, PCT/JP/97/004267, PCT/JP/97/04267, PCT/JP1997/004267, PCT/JP1997/04267, PCT/JP1997004267, PCT/JP199704267, PCT/JP97/004267, PCT/JP97/04267, PCT/JP97004267, PCT/JP9704267, WO 1998/023290 A1, WO 1998023290 A1, WO 1998023290A1, WO 9823290 A1, WO 9823290A1, WO-A1-1998023290, WO-A1-9823290, WO1998/023290A1, WO1998023290 A1, WO1998023290A1, WO9823290 A1, WO9823290A1
InventorsHiroshi Nagase, Jun Utsumi, Takashi Endoh, Toshiaki Tanaka, Junzo Kamei, Kuniaki Kawamura
ApplicantToray Industries, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Antipruritic agent
WO 1998023290 A1
Abstract
An antipruritic agent comprising as the active ingredient an opioid λ receptor agonist useful for the treatment of pruritus in various diseases accompanied by pruritus, and novel morphinane quaternary ammonium salt derivatives and morphinane N-oxide derivatives.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO1995021843A1 *31 Jan 199517 Aug 1995Smithkline Beecham Farmaceutici S.P.A.Azacyclic derivatives
Non-Patent Citations
Reference
1 *See also references of EP0897726A4
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2001074819A1 *2 Apr 200111 Oct 2001Toray Industries, Inc.Analgesics containing morphinan n-oxide derivatives as the active ingredient
WO2003082840A128 Mar 20039 Oct 2003Santen Pharmaceutical Co., Ltd.κ-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE
WO2006109671A1 *6 Apr 200619 Oct 2006Toray Industries, Inc.Crystals of morphinan derivative and process for producing the same
WO2007055184A1 *7 Nov 200618 May 2007Toray Industries, Inc.Therapeutic or prophylactic agent for functional bowel disorder
WO2007072749A1 *15 Dec 200628 Jun 2007Toray Industries, Inc.Antitussive agent
WO2008133297A124 Apr 20086 Nov 2008Toray Industries, Inc.Therapeutic or prophylactic agent for dyskinesia
WO2009044883A13 Oct 20089 Apr 2009Toray Industries, Inc.Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
WO2011093441A128 Jan 20114 Aug 2011Toray Industries, Inc.Therapeutic or prophylactic agent for biliary diseases
WO2012105475A130 Jan 20129 Aug 2012Toray Industries, Inc.Therapeutic or prophylactic agent for cachexia
WO2016052617A1 *30 Sep 20157 Apr 2016国立大学法人筑波大学Nalfurafine-containing preparation for topical application
CN101356176B7 Nov 200621 Dec 2011东丽株式会社功能性肠病的治疗或预防药
CN101848714B3 Oct 200820 Aug 2014东丽株式会社Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
EP0996434A4 *19 Jun 199810 Oct 2001Adolor CorpKappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
EP2042173A228 Mar 20031 Apr 2009Santen Pharmaceutical Co., Ltd.Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
US661730830 Apr 20019 Sep 2003Syn X Pharma, Inc.Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US69606125 Jun 20031 Nov 2005Adolor CorporationKappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US711259828 Mar 200326 Sep 2006Santen Pharmaceutical Co., Ltd.κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
US72946475 Jun 200313 Nov 2007Adolor CorporationKappa agonist compounds and pharmaceutical formulations thereof
US729468830 Apr 200113 Nov 2007Nanogen Inc.Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US741098715 May 200612 Aug 2008Santen Pharmaceutical Co., Ltd.Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
US771866430 Mar 200518 May 2010Toray Industries, Inc.Anti-itching agent
US78039426 Apr 200628 Sep 2010Toray Industries, Inc.Crystals of morphinan derivative and process for producing the same
US80582867 Nov 200615 Nov 2011Toray Industries, Inc.Method for therapy of diarrhea-predominant irritable bowel disorders
US810606515 Dec 200631 Jan 2012Toray Industries, Inc.Antitussive agent
US818325620 Jun 200822 May 2012Toray Industries, Inc.Remedy or preventive for integration dysfunction syndrome
US833844229 Mar 200225 Dec 2012Toray Industries, Inc.Remedies for psychoneurosis
US842066225 Apr 200816 Apr 2013Toray Industries, Inc.Stable solid preparation containing 4,5-epoxymorphinan derivative
US900626230 Jan 201214 Apr 2015Toray Industries, Inc.Therapeutic or prophylactic agent for cachexia
Classifications
International ClassificationA61K31/541, A61P17/04, A61K31/40, A61K31/435, A61K31/4025, A61K31/5377, A61K31/485, C07D489/00, C07D489/08
Cooperative ClassificationC07D489/08, C07D489/00, A61K31/40, A61K31/5377, A61K31/541, A61K31/485, A61K31/4025, A61K31/435
European ClassificationA61K31/40, A61K31/5377, C07D489/00, A61K31/4025, A61K31/485, C07D489/08, A61K31/435, A61K31/541
Legal Events
DateCodeEventDescription
4 Jun 1998AKDesignated states
Kind code of ref document: A1
Designated state(s): AU CA CN JP KR NO NZ US
4 Jun 1998ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
15 Jul 1998WWEWipo information: entry into national phase
Ref document number: 331001
Country of ref document: NZ
24 Jul 1998WWEWipo information: entry into national phase
Ref document number: 1019980705696
Country of ref document: KR
24 Jul 1998ENPEntry into the national phase in:
Ref country code: CA
Ref document number: 2244256
Kind code of ref document: A
Format of ref document f/p: F
Ref document number: 2244256
Country of ref document: CA
11 Aug 1998WWEWipo information: entry into national phase
Ref document number: 1997912539
Country of ref document: EP
24 Aug 1998WWEWipo information: entry into national phase
Ref document number: 09117052
Country of ref document: US
28 Oct 1998121Ep: the epo has been informed by wipo that ep was designated in this application
24 Feb 1999WWPWipo information: published in national office
Ref document number: 1997912539
Country of ref document: EP
15 Nov 1999WWPWipo information: published in national office
Ref document number: 1019980705696
Country of ref document: KR
17 Jan 2006WWGWipo information: grant in national office
Ref document number: 1019980705696
Country of ref document: KR
11 Apr 2007WWGWipo information: grant in national office
Ref document number: 1997912539
Country of ref document: EP